Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02051751
Title A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

breast cancer

Advanced Solid Tumor

head and neck cancer

Therapies

Alpelisib + Paclitaxel

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP


No variant requirements are available.